2. GPCR/G Protein Neuronal Signaling
  3. mGluR
  4. ADX88178 TFA

ADX88178 TFA is an orally active, blood-brain barrier-penetrant, selective positive allosteric modulator of mGluR4, with an EC50 of 3.5 nM against hmGluR4. ADX88178 TFA modulates mGlu4 activity, enhances glutamate-mediated receptor activation, and increases the apparent affinity of glutamate for the receptor. ADX88178 TFA reverses haloperidol-induced catalepsy, potentiates the effects of levodopa (L-DOPA) and quinpirole, but fails to alleviate established abnormal involuntary movements, does not exacerbate L-DOPA-induced dyskinesia, and does not affect forelimb akinesia when administered alone. ADX88178 TFA can be used in research related to L-DOPA-induced dyskinesia and Parkinson's disease.

For research use only. We do not sell to patients.

ADX88178 TFA

ADX88178 TFA Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of ADX88178 TFA:

Other Forms of ADX88178 TFA:

ADX88178 TFA Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE ADX88178 TFA

View All mGluR Isoform Specific Products:

View All Isoforms
mGluR1 mGluR2 mGluR3 mGluR4 mGluR5 mGluR6 mGluR7 mGluR8 mGluR

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

ADX88178 TFA is an orally active, blood-brain barrier-penetrant, selective positive allosteric modulator of mGluR4, with an EC50 of 3.5 nM against hmGluR4. ADX88178 TFA modulates mGlu4 activity, enhances glutamate-mediated receptor activation, and increases the apparent affinity of glutamate for the receptor. ADX88178 TFA reverses haloperidol-induced catalepsy, potentiates the effects of levodopa (L-DOPA) and quinpirole, but fails to alleviate established abnormal involuntary movements, does not exacerbate L-DOPA-induced dyskinesia, and does not affect forelimb akinesia when administered alone. ADX88178 TFA can be used in research related to L-DOPA-induced dyskinesia and Parkinson's disease[1][2].

IC50 & Target[1]

hmGluR4

3.5 nM (EC50)

In Vitro

ADX88178 (30 nM-3 μM) TFA potently enhances glutamate-mediated calcium mobilization in HEK293 cells expressing hmGluR4, with an EC50 of 3.5 nM, and exhibits no intrinsic agonist activity[2].
ADX88178 TFA enhances glutamate-mediated calcium mobilization in HEK293 cells expressing rat mGluR4, with an EC50 of 9.1 nM, and exhibits no intrinsic agonist activity[2].
ADX88178 TFA exerts inhibitory effects of varying intensities on cytochrome P450 enzymes, with the strongest inhibitory activity against CYP1A2 (IC50 = 0.46 μM) and weak inhibitory activity against CYP2D6 (IC50 >50 μM)[2].
ADX88178 (1000 ng/mL) TFA shows low plasma protein binding, with a free fraction of 8.1% in rat plasma and 21.5% in mouse plasma[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ADX88178 TFA Related Antibodies
In Vivo

ADX88178 (10-30 mg/kg; p.o.; single dose 30 min prior to L-DOPA + benserazide) does not reduce pre-established L-DOPA-induced AIMs in 6-hydroxydopamine-lesioned rats[1].
ADX88178 (0.1-10 mg/kg; p.o.) produces dose-dependent reversal of haloperidol-induced catalepsy in male Sprague-Dawley rats, with an ED50 of 1.1 mg/kg and significant effects observed at 3 and 10 mg/kg[2].
ADX88178 (3-30 mg/kg; p.o.; 10 mg/kg; i.p.; 20-60 minutes before L-DOPA or vehicle) alone does not improve forelimb akinesia in 6-OHDA-lesioned male Sprague-Dawley rats, but it dose-dependently potentiates the efficacy of submaximal L-DOPA doses, with full reversal of motor deficits achieved at 30 mg/kg ADX88178 plus 6 mg/kg L-DOPA[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague-Dawley (male, 270-300 g, 6-hydroxydopamine-lesioned, primed with L-DOPA + benserazide to establish stable AIMs)[1]
Dosage: 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose 30 min prior to L-DOPA + benserazide
Result: Failed to produce a significant reduction in total AIMs scores compared to vehicle.
Failed to produce significant effects on axial, forelimb, or orolingual AIMs subtypes.
Animal Model: Sprague-Dawley (male, 260-450 g, haloperidol-induced catalepsy)[2]
Dosage: 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 10 mg/kg
Administration: p.o.
Result: Produced a dose-dependent reversal of catalepsy.
Reduced catalepsy latency to 33.4 seconds (a 62.3% reduction from haloperidol alone) at 3 mg/kg.
Reduced catalepsy latency to 25.7 seconds (a 71.0% reduction from haloperidol alone) at 10 mg/kg.
Achieved an ED50 of 1.1 mg/kg for catalepsy reversal.
Reached an in vivo plasma EC50 of 92 ng/mL (338 nM).
Animal Model: Sprague-Dawley (male, 225-300 g, bilateral striatal 6-hydroxydopamine lesions)[2]
Dosage: 3-30 mg/kg (p.o.); 10 mg/kg (i.p.)
Administration: p.o.; i.p.;
Result: Showed no significant effect on forelimb stepping scores when administered alone at 3, 10, or 30 mg/kg p.o.
Increased forelimb steps to ~18 when coadministered with 6 mg/kg L-DOPA at 3 mg/kg p.o.
Increased forelimb steps to ~23 when coadministered with 6 mg/kg L-DOPA at 10 mg/kg p.o.
Fully reversed forelimb stepping deficit, restoring steps to pre-lesion levels (~35) when coadministered with 6 mg/kg L-DOPA at 30 mg/kg p.o.
Potentiated L-DOPA efficacy at 10 mg/kg i.p., allowing full reversal of akinesia at 60 mg/kg L-DOPA (vs. 120 mg/kg L-DOPA alone).
Molecular Weight

386.35

Formula

C14H13F3N6O2S
SMILES

CC1=C(C2=CNN=C2)N=C(NC3=NC=CC(C)=N3)S1.OC(C(F)(F)F)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

ADX88178 TFA Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

ADX88178ADX 88178ADX-88178mGluRMetabotropic glutamate receptorshumanL-DOPA-induced dyskinesiacytochrome P450 enzymesratSprague-Dawley ratsmGluR46-hydroxydopamine-lesioned ratsParkinson’s diseaseHEK293 cellsglutamateInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
ADX88178 TFA
Cat. No.:
HY-18654A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.